Sector: Health Care
Director information for ZOETIS INC CLASS A (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Antoinette R. Leatherberry | Former Principal at Deloitte; Director | 64 | ["Former Principal at Deloitte","30-year career as a partner at Deloitte","Expertise in technology implementation","Knowledge of change management and large-scale system transformations","Experience with Fortune 500 companies","Insight on employee culture and inclusion","Experience in leading high-performing teams","Expertise in cybersecurity, IT and governance"] | ["Audit","Human Resources","Audit Committee"] | 2026 |
| Frank A. D’Amelio | Former Executive Vice President and Chief Financial Officer of Pfizer Inc.; Independent Director | 68 | ["Former Executive Vice President and Chief Financial Officer of Pfizer Inc.","Exceptional financial acumen","Extensive M&A expertise","Instrumental in establishing Zoetis as a standalone entity from Pfizer","Deep operational experience overseeing global supply chains","Experience with major business transformations","Extensive public company board service","Financially Literate","Audit committee financial expert"] | ["Audit","Human Resources","Audit Committee"] | 2026 |
| Gavin D.K. Hattersley | Former President and Chief Executive Officer at Molson Coors; Independent Director; Chair | 63 | ["strong governance","financial expertise","experience as former director","President and Chief Executive Officer","Chief Financial Officer","insights on brand matters","leadership to the Corporate Governance Committee","Financially Literate","Audit committee financial expert"] | ["Audit","Corporate Governance","Audit Committee","Corporate Governance Committee"] | 2026 |
| Gregory Norden | Former Chief Financial Officer of Wyeth; Independent Director; Chair | 68 | ["Former Chief Financial Officer of Wyeth","Over 20 years of leadership and financial management experience in global healthcare and pharmaceuticals","Exceptional financial and accounting expertise","Knowledge of reporting requirements and disclosure rules","Audit committee responsibilities","Institutional knowledge as chair of the Audit Committee","Expertise in working with internal and external audit teams","Navigating complex financial and compliance matters","Financially Literate","Audit committee financial expert"] | ["Audit","Corporate Governance","Audit Committee","Corporate Governance Committee"] | 2026 |
| Kristin C. Peck | Chief Executive Officer of Zoetis Inc.; Chief Executive Officer (“CEO”) | 54 | ["More than 25 years in business management","20-plus years in the health care and animal health industry","Knowledge of Zoetis since its initial public offering in 2013","Experience in development, implementation and execution of corporate strategy","Strong business experience as Chief Executive Officer"] | [] | 2026 |
| Louise M. Parent | [] | ["Audit Committee","Corporate Governance Committee"] | 2026 | ||
| Mark Stetter | Dean of the University of California, Davis, School of Veterinary Medicine; Independent Director | 65 | ["Dean of the University of California, Davis School of Veterinary Medicine","expertise in veterinary medicine","corporate experience from senior leadership roles at The Walt Disney Company's Animal Kingdom","perspective on product strategy, competitive positioning and R&D pipeline development","connections within the veterinary profession","understanding of future veterinarians' needs"] | ["Human Resources","Quality and Innovation","Quality and Innovation Committee"] | 2026 |
| Michael B. McCallister | Former Chairman of the Board and CEO of Humana Inc.; Chair of the Board | 73 | ["deep and pragmatic expertise in strategic planning","leadership and stability","management of complex issues","digital transformation from senior executive leadership roles at Humana","proven track record of driving innovation-focused growth","leading strategic M&A initiatives","valuable operational expertise","extensive corporate governance acumen","Extensive management and CEO experience","Expertise in strategic planning","Leadership and stability","Management of complex issues","Digital transformation","Track record of driving innovation-focused growth","Leading strategic M&A initiatives","Public company board experience","Corporate governance acumen"] | [] | 2026 |
| Paul M. Bisaro | Former Executive Chairman of Amneal Pharmaceuticals, Inc.; Independent Director | 65 | ["Exceptional global healthcare and pharmaceutical industry expertise","Former Executive Chairman of Amneal Pharmaceuticals, Inc.","Prior senior executive leadership roles including President and CEO of Actavis","Executive Chairman of Allergan","Deep knowledge of manufacturing processes, R&D, product liability and regulatory matters","Valuable strategic M&A acumen","Legal background as a former public company general counsel","Extensive public company board experience","Strong legal and governance expertise"] | ["Corporate Governance","Quality and Innovation","Corporate Governance Committee","Quality and Innovation Committee"] | 2026 |
| Sanjay Khosla | Former EVP and President, Developing Markets of Mondelēz International, Inc.; Independent Director | 74 | ["Former EVP and President, Developing Markets of Mondelēz International, Inc.","Extensive international business expertise","More than 35 years of experience in leadership roles","Deep understanding of global organizational dynamics","Experience in developing markets"] | ["Human Resources","Quality and Innovation","Quality and Innovation Committee"] | 2026 |
| Stephanie Tilenius | Founder of Peak Health and founder and former CEO of Vida Health, Inc.; Independent Director | 58 | ["Founder of Peak Health","Founder and former CEO of Vida Health, Inc.","Commercial and marketing expertise","Strong technology background from extensive Silicon Valley leadership experience including roles at Google, PayPal and eBay","Innovative thinking on marketing, brand and customer engagement strategies","Insights on direct-to-consumer, digital marketing and AI opportunities","Experience leading numerous acquisitions","Financial acumen","AI and digital technology expertise","Pragmatic approach to complex matters"] | ["Audit","Human Resources","Audit Committee"] | 2026 |
| Vanessa Broadhurst | Executive Vice President, Global Corporate Affairs, at Johnson & Johnson | 57 | ["Critical public policy and government affairs expertise","Executive leadership role at Johnson & Johnson","Insights on communications, brand reputation management, marketing and regulatory matters","Extensive commercial experience from senior leadership roles across multiple pharmaceutical companies","Responsibility for global commercial strategy, M&A activity, pipeline development and new product launches","Extensive government relations network","Proven ability to navigate complex product challenges and political environments","Governance acumen from serving on a Fortune 500 executive team"] | ["Corporate Governance","Quality and Innovation","Corporate Governance Committee","Quality and Innovation Committee"] | 2026 |
| Willie M. Reed | Dean Emeritus, Professor of Comparative Pathobiology at the College of Veterinary Medicine at Purdue University; Independent Director; Chair | 71 | ["Dean Emeritus, Professor of Comparative Pathobiology at Purdue University","Expertise in animal healthcare","Knowledge of livestock and pet care sectors","Extensive network and veterinary career spanning more than 40 years","Background in veterinary diagnostics","Active leader in industry conferences","Insights on veterinary workforce issues and trends","Focus on culture and employee engagement"] | ["Corporate Governance","Quality and Innovation (Chair)","Corporate Governance Committee","Quality and Innovation Committee"] | 2026 |
